Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to $2.8 million.

  • Voyager Therapeutics' Change in Accured Expenses rose 14217.28% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.4 million, marking a year-over-year increase of 77538.46%. This contributed to the annual value of -$2.7 million for FY2024, which is 12944.38% down from last year.
  • According to the latest figures from Q3 2025, Voyager Therapeutics' Change in Accured Expenses is $2.8 million, which was up 14217.28% from $3.0 million recorded in Q2 2025.
  • In the past 5 years, Voyager Therapeutics' Change in Accured Expenses ranged from a high of $5.8 million in Q4 2023 and a low of -$9.3 million during Q1 2024
  • Moreover, its 5-year median value for Change in Accured Expenses was $445000.0 (2021), whereas its average is $29315.8.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first soared by 106584.27% in 2022, then tumbled by 752704.92% in 2024.
  • Quarter analysis of 5 years shows Voyager Therapeutics' Change in Accured Expenses stood at -$423000.0 in 2021, then tumbled by 1007.33% to -$4.7 million in 2022, then soared by 223.21% to $5.8 million in 2023, then crashed by 52.71% to $2.7 million in 2024, then rose by 3.74% to $2.8 million in 2025.
  • Its last three reported values are $2.8 million in Q3 2025, $3.0 million for Q2 2025, and -$5.1 million during Q1 2025.